Cohance’s current executive Chairman Vivek Sharma will be stepping down for personal reasons, but will continue to remain with the company for the next nine months as an advisor and help in a smooth transition.
Vohra had stepped down as Group CEO at Cipla in October last year, completing his notice period on March 31, 2026. Achin Gupta was named as his successor.
As of last Friday’s close, shares of Cohance Lifesciences were the third-worst performers on the Nifty Smallcap index, with losses of 31%.”Cohance’s technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike,” Umang Vohra said in his statement.
The company’s capabilities span across complex APIs, ADCs, and Oligonucleotides, along with complex intermediates, performance materials and specialty ingredients.
Cohance called Vohra’s appointment a deliberate, strategic decision taken by the board to bring in a leader whose profile is specifically suited to the company’s demands for its transformation and the next phase of growth.
Shares of Cohance Lifesciences are trading 20% higher at ₹430.2. The stock has recovered nearly half of its 2026 loss in just one trading session, but is still down 20% so far this year.
First Published: Apr 27, 2026 9:33 AM IS
